Laboratory markers of platelet activation and their clinical significance

Current Opinion in Hematology

Volumn 6, Issue 5, 1999, Pages 342-348

  Michelson, A D ^a   Furman, M I ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CD63 ANTIGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN; HEPARIN; LYSOSOMAL ASSOCIATED MEMBRANE PROTEIN 1; MEMBRANE PROTEIN; PADGEM PROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; CORONARY ARTERY DILATATION; DIABETES MELLITUS; DISEASE MARKER; DRUG MONITORING; FLOW CYTOMETRY; HEART MUSCLE ISCHEMIA; HUMAN; LEUKOCYTE AGGREGATION; PERIPHERAL VASCULAR DISEASE; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

BIOLOGICAL MARKERS; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; FLOW CYTOMETRY; HUMAN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0033302953     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199909000-00012     Document Type: Review

References (60)

1. Flow cytometry: A clinical test of platelet function
2. The European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function
3. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation
4. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies
5. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion
6. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers
7. Monoclonal antibodies specific for a conformationally altered state of fibrinogen
8. Direct detection of activated platelets and platelet-derived microparticles in humans
9. Endogenous platelet fibrinogen: Its modulation after surface expression is related to size-selective access to and conformational changes in the bound fibrinogen
10. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation
11. PADGEM protein: A receptor that mediates the interaction of activated platelets with neutrophils and monocytes
12. Studies with a monoclonal antibody against activated platelets: Evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation
13. Identification and characterization of LAMP-1 as an activation-dependent platelet surface glycoprotein
14. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
15. Characterization of an anti-thrombospondin monoclonal antibody (P8) that inhibits human blood platelet functions: Normal binding of P8 to thrombin-activated Glanzmann thrombasthenic platelets
16. Mechanisms for expression of thrombospondin on the platelet cell surface
17. p-155, A multimeric platelet protein that is expressed on activated platelets
18. Multimerin is found in the alpha-granules of resting platelets and is synthesized by a megakaryocytic cell line
19. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity
20. Platelet-derived microparticles express high affinity receptors for factor VIII
21. The use of flow cytometry to study platelet activation
22. The platelet membrane glycoprotein IIb-IIIa complex
23. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets
24. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium
25. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible
26. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function
27. P-selectin and platelet clearance
28. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: Methods and clinical studies
29. The cleaved peptide of the thrombin receptor is a strong platelet agonist
30. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
31. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors
32. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial: Thrombolysis in Myocardial Infarction
33. Platelet activation and coronary stent implantation: Effect of antithrombotic therapy
34. Antiplatelet effect of ticlopidine after coronary stenting
35. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA
36. Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis
37. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia
38. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: Role of nitric oxide
39. A sensitive flow cytometric assay for circulating platelet-leucocyte aggregates
40. Patients with venous stasis ulceration have increased monocyte-platelet aggregation
41. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease: Effects of intravenous magnesium
42. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets
43. Increased neutrophil-platelet adhesion in patients with unstable angina
44. Cardiopulmonary bypass induces leukocyte-platelet adhesion
45. Leukocyte activation with platelet adhesion after coronary angioplasty: A mechanism for recurrent disease?
46. Platelet hyporeactivity in very low birth weight neonates
47. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty
48. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement
49. Measurement of glycoprotein IIb/IIIa blockade by flow cytometry with fluorescein isothiocyanate-conjugated crotavirin, a member of disintegrins
50. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy
51. Rapid platelet-function assay: An automated and quantitative cartridge-based method
52. Decreased content and surface expression of alpha-granule membrane protein GMP-140 in one of two types of platelet alpha delta storage pool deficiency
53. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane: Studies in Scott syndrome: An isolated defect in platelet procoagulant activity
54. Whole blood analysis of reticulated platelets: Improvements of detection and assay stability
55. Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves
56. Procoagulant activity of platelet-derived microparticles in whole blood: Differences between neonates and adults
57. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
58. Platelet activation in Alzheimer disease
59. The platelet function defect of cardiopulmonary bypass
60. Effect of strenuous exercise on platelet activation site and reactivity